CMS(00867): The innovative drug phosphorus kitotinib cream has been approved for the Chinese market, becoming the first and only targeted therapy approved for the treatment of vitiligo in China.
Kangze Pharmaceutical (00867) announced that its subsidiary Demai Pharmaceutical Co., Ltd. ("Demai Pharmaceutical"), an innovative pharmaceutical company specializing in skin health, is applying for independent listing on the main board of the Hong Kong Stock Exchange. On January 30, 2026, it obtained approval from the China National Medical Products Administration (NMPA) for the phosphorus luiketini cream (vitiligo indication) new drug application (NDA). The product is used to treat non-segmental vitiligo with facial involvement in children aged 12 and above and adult patients. It is the first and only targeted drug approved in China for the treatment of vitiligo, meeting a significant unmet clinical need.
CMS(00867) announced that its subsidiary, Demit Medical Limited ("Demit Medical"), a innovative pharmaceutical company specializing in skin health, is applying for an independent listing on the main board of the Hong Kong Stock Exchange. On January 30, 2026, Demit Medical obtained approval from the China National Medical Products Administration (NMPA) for its new drug application (NDA) for phosphatidylinositol-lysine-niacinamide phosphatidylcholine cream (indications for vitiligo). The product is for the treatment of non-segmental vitiligo in children aged 12 and above and adult patients with facial involvement. It is the first and only targeted drug approved in China for the treatment of vitiligo, meeting a huge unmet clinical need.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
